Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Endocrine 1

Conditions

Pituitary Neoplasms 1

Interventions

Everolimus 10lanreotide 4Capecitabine 4pasireotide 3lutetium Lu 177 dotatate 3lenvatinib 3fosbretabulin 3Temozolomide 3Sorafenib 3Paclitaxel 3Octreotide 3Nivolumab 3Magnetic Resonance Spectroscopy 3Filgrastim 3Erlotinib Hydrochloride 3Doxorubicin 3trifluridine tipiracil drug combination 2surufatinib 2pembrolizumab 2pegfilgrastim 2gallium Ga 68 dotatate 2durvalumab 2dactolisib 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Sunitinib 2Rosiglitazone 2Radiotherapy 2Panobinostat 2Mitotane 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Endoscopic Mucosal Resection × Endocrine × Clear all
NCT03515603 2023-05-17

Endocrine Outcome of Surgery for Pituitary Adenoma

University of Ulm

Phase NA Terminated
36 enrolled
Endocrine

Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡